{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-001700","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.134008+00:00","generated_at":"2026-06-08T07:03:05.808221+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Edgewise Q3 net loss $25.7M; starts pivotal GRAND CANYON study for EDG-5506","bullets":["Cash and equivalents ~$290M; Q3 net loss $25.7M ($0.41/share) vs $21.5M prior quarter.","Initiated GRAND CANYON, global pivotal study of EDG-5506 in Becker MD, aiming for ~120 patients.","LYNX Phase 2 trial for Duchenne expanding with new cohort; interim data expected H1 2024.","Phase 1 trial of EDG-7500 for hypertrophic cardiomyopathy under way; Phase 1b planned H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-001700","json":"https://secwatch.observer/filing/0001157523-23-001700.json","markdown":"https://secwatch.observer/filing/0001157523-23-001700.md","text":"https://secwatch.observer/filing/0001157523-23-001700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000115752323001700/0001157523-23-001700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000115752323001700/a53795839.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:03:05.808221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fa2b7f0c3208ceb5c4ca7b1e08550a0f101d9998","claim":"Edgewise Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Edgewise Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1710072/000115752323001700/0001157523-23-001700-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}